WHO Grade 3 Glioma Not Yet Recruiting Phase 2 Trials for Olutasidenib (DB16267)

Also known as: WHO Grade III Gliomas / Grade III Glioma / WHO Grade III Glioma

IndicationStatusPhase
DBCOND0146359 (WHO Grade 3 Glioma)Not Yet Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT06161974Study of Olutasidenib and Temozolomide in HGGTreatment